Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets in Patients With Mild to Moderate Essential Hypertension Not Controlled After 4 Weeks of Monotherapy With Amlodipine Or Levamlodipine Alone

NCT06771245 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06771245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06771245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets in Patients With Mild to Moderate Essential Hypertension Not Controlled After 4 Weeks of Monotherapy With Amlodipine Or Levamlodipine Alone
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 24, 2025
Completion date
October 30, 2026
Enrollment
606 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mild-to-moderate essential hypertension